Re-evaluating herd protection by Vi typhoid vaccine in a cluster randomized trial.

Clinical trial registration: ClinicalTrials.gov, NCT00125008 Vi polysaccharide vaccine cluster randomized trial fried egg design typhoid fever vaccine effectiveness

Journal

International health
ISSN: 1876-3405
Titre abrégé: Int Health
Pays: England
ID NLM: 101517095

Informations de publication

Date de publication:
01 01 2020
Historique:
received: 26 04 2019
revised: 04 07 2019
accepted: 11 07 2019
pubmed: 15 10 2019
medline: 18 4 2020
entrez: 15 10 2019
Statut: ppublish

Résumé

In a cluster randomized trial (CRT) of a Vi polysaccharide vaccine against typhoid in the slums of Kolkata we found evidence of vaccine herd protection. However, transmission of typhoid into clusters from the outside likely occurred in this densely populated setting, which could have diminished our estimates of vaccine herd protection. Eighty clusters (40 in each arm) were randomised to receive a single dose of either Vi or inactivated hepatitis A vaccine. We analysed protection for the entire cluster and for subclusters consisting of residents of the innermost households. During 2 y of follow-up, total protection was 61% (95% CI 41 to 75), overall protection was 57% (95% CI 37 to 71) and indirect protection was 44% (95% CI 2 to 69). Analyses of the innermost 75% and 50% of households of the clusters showed similar findings. However, in the innermost 25% of households of the clusters, total protection was 82% (95% CI 48 to 94) and overall protection was 66% (95% CI 27 to 84). There was not a sufficient sample size to demonstrate such a trend for indirect protection in these innermost households. The findings suggest that analyses of the entire cluster may have led to underestimation of herd protection against typhoid by Vi vaccine and that restriction of the analyses to the inner subclusters may have led to a more accurate estimation of vaccine herd effects.

Sections du résumé

BACKGROUND
In a cluster randomized trial (CRT) of a Vi polysaccharide vaccine against typhoid in the slums of Kolkata we found evidence of vaccine herd protection. However, transmission of typhoid into clusters from the outside likely occurred in this densely populated setting, which could have diminished our estimates of vaccine herd protection.
METHODS
Eighty clusters (40 in each arm) were randomised to receive a single dose of either Vi or inactivated hepatitis A vaccine. We analysed protection for the entire cluster and for subclusters consisting of residents of the innermost households.
RESULTS
During 2 y of follow-up, total protection was 61% (95% CI 41 to 75), overall protection was 57% (95% CI 37 to 71) and indirect protection was 44% (95% CI 2 to 69). Analyses of the innermost 75% and 50% of households of the clusters showed similar findings. However, in the innermost 25% of households of the clusters, total protection was 82% (95% CI 48 to 94) and overall protection was 66% (95% CI 27 to 84). There was not a sufficient sample size to demonstrate such a trend for indirect protection in these innermost households.
CONCLUSIONS
The findings suggest that analyses of the entire cluster may have led to underestimation of herd protection against typhoid by Vi vaccine and that restriction of the analyses to the inner subclusters may have led to a more accurate estimation of vaccine herd effects.

Identifiants

pubmed: 31608962
pii: 5586242
doi: 10.1093/inthealth/ihz069
pmc: PMC6964216
doi:

Substances chimiques

Typhoid-Paratyphoid Vaccines 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-42

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Références

Am J Epidemiol. 1997 Nov 15;146(10):789-803
pubmed: 9384199
Lancet. 1987 Nov 21;2(8569):1165-9
pubmed: 2890805
Wkly Epidemiol Rec. ;92(48):729-47
pubmed: 29192459
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S74-S82
pubmed: 30845333
Int J Epidemiol. 2019 Aug 1;48(4):1252-1261
pubmed: 30968110
Bull World Health Organ. 2008 Apr;86(4):260-8
pubmed: 18438514
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Lancet Infect Dis. 2011 Jun;11(6):482-7
pubmed: 21616458
Lancet. 2017 Dec 2;390(10111):2472-2480
pubmed: 28965718
N Engl J Med. 2009 Jul 23;361(4):335-44
pubmed: 19625715
N Engl J Med. 1987 Oct 29;317(18):1101-4
pubmed: 3657877

Auteurs

Mohammad Ali (M)

Johns Hopkins Bloomberg School of Public Health, 615, N Wolfe Street, Baltimore, MD-21205, USA.

Dipika Sur (D)

National Institute of Cholera and Enteric Diseases, P-33 CIT Road, Scheme XM, Beliaghata, Kolkata, India.

Suman Kanungo (S)

National Institute of Cholera and Enteric Diseases, P-33 CIT Road, Scheme XM, Beliaghata, Kolkata, India.

Firdausi Qadri (F)

International Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani Mohakhali, Dhaka 1212, Bangladesh.

Deok Ryun Kim (DR)

International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Republic of Korea.

Taufiqul Islam (T)

International Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani Mohakhali, Dhaka 1212, Bangladesh.

Justin Im (J)

International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Republic of Korea.

Faisal Ahmmed (F)

International Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani Mohakhali, Dhaka 1212, Bangladesh.

Yun Chon (Y)

International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Republic of Korea.

Ashraful Islam Khan (AI)

International Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani Mohakhali, Dhaka 1212, Bangladesh.

K Zaman (K)

International Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani Mohakhali, Dhaka 1212, Bangladesh.

Florian Marks (F)

International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Republic of Korea.
Department of Medicine, University of Cambridge, Cambridge, UK.

Shanta Dutta (S)

National Institute of Cholera and Enteric Diseases, P-33 CIT Road, Scheme XM, Beliaghata, Kolkata, India.

Sujit K Bhattacharya (SK)

National Institute of Cholera and Enteric Diseases, P-33 CIT Road, Scheme XM, Beliaghata, Kolkata, India.

John D Clemens (JD)

International Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani Mohakhali, Dhaka 1212, Bangladesh.
UCLA Fielding School of Public Health, Los Angeles, CA 90095-1772, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH